Related Experiment Videos
The HLDA8 blind panel: findings and conclusions
Bernadette Swart1, Mikhail P Salganik, Matthew P Wand
1Child Health Research Institute, Women's and Children's Hospital and Department of Paediatrics, University of Adelaide, 72 King William Rd, North Adelaide, 5006, Australia.
Journal of Immunological Methods
|August 30, 2005
Summary
This study identified 31 novel antibodies with specificities for known molecules, including MHC class II and CD45, from a blind panel. Further analysis confirmed antibody identities through immunohistochemical and Western blot techniques.
Area of Science:
- Immunology
- Cell Biology
Background:
- The Human Leukocyte Differentiation Antigen (HLDA) workshops aim to characterize cell surface antigens using monoclonal antibodies.
- Many submitted antibodies lack defined specificity, necessitating rigorous validation studies.
Purpose of the Study:
- To identify the specificities of unknown monoclonal antibodies submitted to the HLDA8 workshop.
- To validate antibody specificities using a blind panel approach and complementary techniques.
Main Methods:
- A blind panel study involving 101 unknown antibodies, 5 negative controls, and 27 positive controls (total 133 antibodies).
- Immunohistochemical and Western blot analyses were employed to compare antibodies with similar staining patterns.
Main Results:
- 31 of the 101 unknown antibodies were identified as specific for known molecules.
- Identified specificities included major histocompatibility complex (MHC) class II antigens, CD45 isoforms, and the Dombrock antigen.
- Antibody pairs with similar staining patterns were confirmed as identical.
Conclusions:
- The blind panel study successfully identified specificities for a subset of previously uncharacterized antibodies.
- Immunohistochemistry and Western blotting are effective methods for confirming antibody identity and specificity.